塞里斯制药
XERS
10.31
+0.24
+2.38%
塞里斯制药
US · XERS
#2862 按市值排名
上市于 2018
10.31
+0.24
+2.38%
实时 - 追踪5344个代码 - 心跳于337秒前
· 2026-10-16 19:30
✦ 量化股权信号 计算方式说明
减持
- 最近一期（2026/Q3）披露持股的机构数量减少了1家。
- 机构持股总比例下降了4.3个百分点。
机构持股
- 机构持股比例
- 60.85% -4.29pp
- 机构数量
- 281 -1
- 数据截至
- 2026/Q3 较上一报告期
持股变动 vs 资金流向
方向一致机构在上一报告期减持了股份，同时该股在最近20个交易日的主力资金呈净流出——两者方向一致。
机构持股变动数据按季度发布且存在滞后；资金流向数据为每日更新。请将其作为方向性的交叉验证参考，而非精确的择时信号。
持股人类型
Mutual Fund39.06%
Hedge Fund14.63%
Public Company3.64%
Individual/Insider3.44%
Insurance Company1.11%
Government Pension Fund0.81%
Private Company0.80%
Sovereign Wealth Fund0.44%
VC/PE Fund0.26%
Other35.80%
主要股东 截至 2026-06-30
BlackRock
7.97% · 14.53M 股
Vanguard Capital Management, LLC
4.70% · 8.56M 股
D. E. Shaw & Co., L.P.
4.28% · 7.80M 股
State Street Global Advisors
2.64% · 4.82M 股
Geode Capital Management, LLC
2.59% · 4.72M 股
Teachers Insurance and Annuity Association-College Retirement Equities Fund
2.33% · 4.25M 股
Rosalind Advisors, Inc.
1.60% · 2.91M 股
Qube Research & Technologies Ltd
1.59% · 2.89M 股
Vanguard Portfolio Management, LLC
1.44% · 2.63M 股
Wellington Management Group
1.30% · 2.37M 股
条形长度是相对于此处列出的最大股东而言，并非相对于公司100%股权。
内部人持股
共追踪50份申报 · 18次买入 · 32次卖出
| 姓名 | 职务 | 持股比例 |
|---|---|---|
| Kevin McCulloch | Chief Commercial Officer | 0.89% |
| John Shannon | President | 0.85% |
| Steven Pieper | Chief Financial Officer | 0.51% |
| John Johnson | Independent Non-Executive Director | 0.37% |
| Beth Hecht | Chief Legal Officer | 0.35% |
| Garheng Albert Kong | Independent Non-Executive Director | 0.12% |
| Jeffrey Sherman | Independent Director | 0.10% |
| Marla Persky | Independent Director | 0.07% |
| Barbar-Jean Bormann-Kennedy | Independent Director | 0.07% |
| Dawn Halkuff | Independent Director | 0.06% |
内部人交易 最近的 Form 4 申报记录
| 日期 | 姓名 | 职务 | 类型 | 股数 | 价格 |
|---|---|---|---|---|---|
| 2026-09-30 | Beth Hecht | Chief Legal Officer | Automatic Disposition | -16,666 | $9.41 |
| 2026-09-30 | Kevin McCulloch | Chief Commercial Officer | Automatic Disposition | -15,000 | $9.41 |
| 2026-09-30 | Steven Pieper | Chief Financial Officer | Automatic Disposition | -5,000 | $9.41 |
| 2026-09-27 | Kevin McCulloch | Chief Commercial Officer | Automatic Disposition | -25,000 | $10.00 |
| 2026-08-31 | Beth Hecht | Chief Legal Officer | Automatic Disposition | -16,666 | $8.49 |
| 2026-08-31 | Kevin McCulloch | Chief Commercial Officer | Automatic Disposition | -15,000 | $8.49 |
| 2026-08-31 | Steven Pieper | Chief Financial Officer | Automatic Disposition | -5,000 | $8.50 |
| 2026-08-11 | Steven Pieper | Chief Financial Officer | Automatic Disposition | -5,000 | $8.50 |
| 2026-08-02 | Beth Hecht | Chief Legal Officer | Automatic Disposition | -16,666 | $8.01 |
| 2026-08-02 | Kevin McCulloch | Chief Commercial Officer | Automatic Disposition | -15,000 | $8.02 |
| 2026-07-31 | John Shannon | President | Sale to Issuer | -36,645 | $8.08 |
| 2026-07-31 | Kevin McCulloch | Chief Commercial Officer | Sale to Issuer | -21,918 | $8.08 |
| 2026-07-06 | Steven Pieper | Chief Financial Officer | Automatic Disposition | -45,000 | $8.50–8.52 |
| 2026-07-06 | Steven Pieper | Chief Financial Officer | Intent to Sell (Form 144) | -27,600 | $8.37 |
| 2026-07-05 | Steven Pieper | Chief Financial Officer | Intent to Sell (Form 144) | -17,400 | $8.28 |
| 2026-06-30 | Beth Hecht | Chief Legal Officer | Automatic Disposition | -16,666 | $8.03 |
| 2026-06-30 | Nerissa Kreher | Director | Other Acquisition | +33,582 | -- |
| 2026-06-30 | Nerissa Kreher | Director | Other Derivative Acquisition | +37,910 | $8.00 |
| 2026-06-30 | Kevin McCulloch | Chief Commercial Officer | Automatic Disposition | -90,000 | $8.03 |
| 2026-06-03 | Garheng Albert Kong | Independent Non-Executive Director | Other Acquisition | +24,193 | -- |
Form 4 申报记录，每家公司显示最新的一批。"Other Derivative Acquisition"（其他衍生品获取）类目多为限制性股票/期权归属，并非公开市场买入——具体类型见"类型"列。
报价时间 2026-10-16 19:30:04 · 仅供参考，不构成投资建议，也未考虑您的具体情况。
塞里斯制药 讨论区 0 条评论